vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Douglas Emmett Inc (DEI). Click either name above to swap in a different company.
Douglas Emmett Inc is the larger business by last-quarter revenue ($249.4M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 1.8%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 0.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Douglas Emmett Inc is a leading real estate investment trust (REIT) that owns, operates, and acquires high-quality office and multifamily residential properties. Its core operation areas are high-barrier-to-entry markets including Los Angeles in California and Honolulu in Hawaii, serving premium commercial and residential tenant segments.
AXSM vs DEI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $249.4M |
| Net Profit | — | $-6.8M |
| Gross Margin | — | 62.2% |
| Operating Margin | -33.1% | — |
| Net Margin | — | -2.7% |
| Revenue YoY | 57.4% | 1.8% |
| Net Profit YoY | — | -670.7% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $249.4M | ||
| Q3 25 | $171.0M | $250.6M | ||
| Q2 25 | $150.0M | $252.4M | ||
| Q1 25 | $121.5M | $251.5M | ||
| Q4 24 | $118.8M | $245.0M | ||
| Q3 24 | $104.8M | $250.8M | ||
| Q2 24 | $87.2M | $245.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-6.8M | ||
| Q3 25 | $-47.2M | $-10.9M | ||
| Q2 25 | $-48.0M | $-5.8M | ||
| Q1 25 | $-59.4M | $39.8M | ||
| Q4 24 | $-74.9M | $-888.0K | ||
| Q3 24 | $-64.6M | $4.6M | ||
| Q2 24 | $-79.3M | $10.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 62.2% | ||
| Q3 25 | — | 63.6% | ||
| Q2 25 | — | 63.2% | ||
| Q1 25 | — | 64.4% | ||
| Q4 24 | — | 63.5% | ||
| Q3 24 | — | 62.2% | ||
| Q2 24 | — | 66.2% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -2.7% | ||
| Q3 25 | -27.6% | -4.3% | ||
| Q2 25 | -32.0% | -2.3% | ||
| Q1 25 | -48.9% | 15.8% | ||
| Q4 24 | -63.1% | -0.4% | ||
| Q3 24 | -61.7% | 1.8% | ||
| Q2 24 | -91.0% | 4.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.04 | ||
| Q3 25 | $-0.94 | $-0.07 | ||
| Q2 25 | $-0.97 | $-0.04 | ||
| Q1 25 | $-1.22 | $0.24 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $0.03 | ||
| Q2 24 | $-1.67 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $340.8M |
| Total DebtLower is stronger | $70.0M | $5.5B |
| Stockholders' EquityBook value | — | $1.9B |
| Total Assets | $713.6M | $9.3B |
| Debt / EquityLower = less leverage | — | 2.91× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $340.8M | ||
| Q3 25 | $325.3M | $408.5M | ||
| Q2 25 | $303.0M | $426.9M | ||
| Q1 25 | $300.9M | $525.7M | ||
| Q4 24 | $315.4M | $444.6M | ||
| Q3 24 | $327.3M | $544.2M | ||
| Q2 24 | $315.7M | $561.1M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $5.5B | ||
| Q3 25 | — | $5.6B | ||
| Q2 25 | — | $5.6B | ||
| Q1 25 | — | $5.6B | ||
| Q4 24 | — | $5.5B | ||
| Q3 24 | — | $5.5B | ||
| Q2 24 | — | $5.5B |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.9B | ||
| Q3 25 | $73.7M | $1.9B | ||
| Q2 25 | $73.1M | $2.0B | ||
| Q1 25 | $53.2M | $2.0B | ||
| Q4 24 | $57.0M | $2.1B | ||
| Q3 24 | $92.9M | $2.1B | ||
| Q2 24 | $102.9M | $2.2B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $9.3B | ||
| Q3 25 | $669.3M | $9.4B | ||
| Q2 25 | $639.8M | $9.4B | ||
| Q1 25 | $596.7M | $9.6B | ||
| Q4 24 | $568.5M | $9.4B | ||
| Q3 24 | $561.5M | $9.5B | ||
| Q2 24 | $548.2M | $9.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.91× | ||
| Q3 25 | — | 2.85× | ||
| Q2 25 | — | 2.78× | ||
| Q1 25 | — | 2.75× | ||
| Q4 24 | — | 2.67× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | 2.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $386.9M |
| Free Cash FlowOCF − Capex | — | $194.5M |
| FCF MarginFCF / Revenue | — | 78.0% |
| Capex IntensityCapex / Revenue | — | 77.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $376.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $386.9M | ||
| Q3 25 | $1.0M | $109.8M | ||
| Q2 25 | $-32.4M | $81.3M | ||
| Q1 25 | $-43.4M | $132.6M | ||
| Q4 24 | $-26.2M | $408.7M | ||
| Q3 24 | $-18.6M | $103.7M | ||
| Q2 24 | $-30.1M | $91.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $194.5M | ||
| Q3 25 | $988.0K | $61.9M | ||
| Q2 25 | $-32.4M | $30.2M | ||
| Q1 25 | $-43.7M | $90.3M | ||
| Q4 24 | $-26.2M | $241.4M | ||
| Q3 24 | $-18.7M | $63.2M | ||
| Q2 24 | $-30.2M | $52.2M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 78.0% | ||
| Q3 25 | 0.6% | 24.7% | ||
| Q2 25 | -21.6% | 11.9% | ||
| Q1 25 | -36.0% | 35.9% | ||
| Q4 24 | -22.1% | 98.5% | ||
| Q3 24 | -17.9% | 25.2% | ||
| Q2 24 | -34.6% | 21.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 77.1% | ||
| Q3 25 | 0.0% | 19.1% | ||
| Q2 25 | 0.0% | 20.3% | ||
| Q1 25 | 0.3% | 16.8% | ||
| Q4 24 | 0.0% | 68.3% | ||
| Q3 24 | 0.1% | 16.1% | ||
| Q2 24 | 0.1% | 16.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 22.46× | ||
| Q2 24 | — | 8.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
DEI
| Rental Revenue And Tenant Recovery Revenue | $169.4M | 68% |
| Multifamily Segment | $49.9M | 20% |
| Parking Revenue And Other Income | $30.2M | 12% |
